profit from every $100 of sales.
$0$100
So-Young International
$1.99-2.93% today
-55.5% in 1 year
1-year low $1.321-year high $4.47
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What So-Young International sold, what it kept, and what it did with the cash.
Sales went from CN¥1.26 billion in 2022 to CN¥1.52 billion in 2025, with -CN¥242 million of profit last year.
SalesProfit
So-Young International vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| So-Young International | No profit yet | ||
 GE HealthCare Technologies | 18.2× · Fair price | ||
 Tempus AI | No profit yet | ||
 BrightSpring Health Services | 72.2× · Very expensive | ||
 HealthEquity | 39.2× · Expensive |
AI analysis
An AI analyst reads So-Young International's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,258 | 1,498 | 1,467 | 1,523 | |
| 865 | 954 | 899 | 728 | |
| -103 | -61 | -84 | -266 | |
| -56 | -15 | -39 | -209 | |
| -66 | 21 | -590 | -242 | |
| -0.61 | 0.21 | -5.72 | -2.39 | |
| 68.7% | 63.7% | 61.3% | 47.8% | |
| -8.2% | -4.1% | -5.8% | -17.5% | |
| -5.2% | 1.4% | -40.2% | -15.9% |
Balance sheet
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,198 | 3,215 | 2,735 | 2,650 |
| Cash | 694 | 426 | 588 | 418 |
| Total debt | 71 | 146 | 240 | 300 |
| Total liabilities | 590 | 653 | 776 | 981 |
| 2,498 | 2,444 | 1,839 | 1,553 | |
| 107 | 101 | 103 | 101 | |
| -3.2% | -1.9% | -3.2% | -11.4% | |
| -2.6% | 0.9% | -32.1% | -15.6% |
Cash flow
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -113 | 23 | -26 | -105 | |
| 16 | 51 | 63 | 197 | |
| -129 | -29 | -88 | -302 | |
| Dividends paid | 0 | 0 | 44 | 19 |
| 15 | 126 | 18 | 15 | |
| 43 | 36 | 33 | 9 |
Valuation
- –
- –
- –
- 1.6×
- 0.9×
- –
- –
- -22.6%
- -18.1%
- 1.4%
Profitability
- 47.8%
- -17.5%
- -15.9%
- -17.5%
- -13.4%
- -8.6%
- -14.3%
- -9.1%
- -14.2%
- 9.0%
Growth
- +6.6%
- –
- −242.5%
- –
- −1.2%
Financial health
- -0.6×
- 0.19
- 11.3%
- –
- 1.89
- 1.60
- 0.57
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 948
Bottom 13%of 871
Bottom 33%of 868
Bottom 3%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 25, 2026 | -0.13 | -0.10 | −33.5% |
| Nov 17, 2025 | -0.09 | -0.68 | +86.8% |
| Aug 15, 2025 | -0.04 | -0.33 | +88.0% |
| May 16, 2025 | -0.04 | -0.34 | +88.2% |
| Mar 28, 2025 | -0.07 | 0.09 | −177.8% |
| Nov 20, 2024 | 0.03 | 0.02 | +50.0% |
| Aug 23, 2024 | 0.02 | 0.21 | −90.5% |
| Mar 20, 2024 | 0.06 | 0.15 | −60.0% |
1.4%of the share price, paid each year
On $1,000 invested$14a year at today's yield, before tax
–per share
Raised–not every year
Paid per share, each year
$0.06 in 2024 → $0.03 in 2025
How safe it looks
-7.9% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
48No pass
Philip Fisher
40No pass
Peter Lynch
38No pass
Joel Greenblatt
0No pass
Charlie Munger
42No pass
Terry Smith
44No pass
Questions about So-Young International
Is So-Young International a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the So-Young International AI analysis
What does So-Young International do?
So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments in the People's Republic of China and internationally. It is in Medical - Healthcare Information Services.
Does So-Young International pay a dividend?
Yes. At today's price the dividend is 1.4% a year. In 2025 it paid out $19.0 million in dividends.
Is So-Young International stock halal?
Yes. So-Young International passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has So-Young International stock done over the past year?
Down 55.5% over the past twelve months, to $1.99. It traded between $1.32 and $4.47 and is 55.5% below its high.
Who are So-Young International's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, Tempus AI, BrightSpring Health Services and HealthEquity. The peers table on this page compares their profit, growth and price with So-Young International's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.